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Abstract
Expression of Piwi proteins is confined to early development and stem cells during which they suppress transposon
migration via DNA methylation to ensure genomic stability. Piwi’s genomic protective function conflicts with reports that its
human ortholog, Hiwi, is expressed in numerous cancers and prognosticates shorter survival. However, the role of Hiwi in
tumorigenesis has not been examined. Here we demonstrate that (1) over-expressing Hiwi in sarcoma precursors inhibits
their differentiation in vitro and generates sarcomas in vivo; (2) transgenic mice expressing Hiwi (mesodermally restricted)
develop sarcomas; and (3) inducible down-regulation of Hiwi in human sarcomas inhibits growth and re-establishes
differentiation. Our data indicates that Hiwi is directly tumorigenic and Hiwi-expressing cancers may be addicted to Hiwi
expression. We further show that Hiwi associated DNA methylation and cyclin-dependent kinase inhibitor (CDKI) silencing is
reversible along with Hiwi-induced tumorigenesis, via DNA-methyltransferase inhibitors. Our studies reveal for the first time
not only a novel oncogenic role for Hiwi as a driver of tumorigenesis, but also suggest that the use of epigenetic agents may
be clinically beneficial for treatment of tumors that express Hiwi. Additionally, our data showing that Hiwi-associated DNA
hyper-methylation with subsequent genetic and epigenetic changes favoring a tumorigenic state reconciles the conundrum
of how Hiwi may act appropriately to promote genomic integrity during early development (via transposon silencing) and
inappropriately in adult tissues with subsequent tumorigenesis.
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Introduction
In all model systems examined, Piwi family members are
expressed in stem cells, including germ and hematopoietic, and are
essential for germ line and/or somatic stem cell self-renewal
[1,2,3,4]. Although the exact mechanism is still unclear even in the
most studied models (e.g., drosophila, mice [1,2,3,4]), Piwi appears
to ensure stem cell maintenance by inhibiting transposon
migration [5,6] during early development via an indirect (since
Hiwi has no known direct chromatin modifiying function)
upregulation of epigenetically based silencing machinery (i.e.,
DNA methylation) [7,8,9]. Specifically, previous studies have
shown that transposon-specific DNA-methylation was reduced
and transposon activity was elevated following silencing of Hiwi (or
its orthologs). Although transposons promote evolutionary diver-
sity in lower organisms, their unchecked migration in higher
organisms can result in disruption of genomic integrity [10] and
thus Piwi proteins may have developed as an evolutionary defense
system for multi-cellular species.
Based on the data that implicate Piwi in transposon silencing,
maintenance of genome integrity and exclusively embryonic and/
or stem cells expression, it is surprising that a growing body of
studies reveal that Hiwi, the human ortholog of Piwi, is expressed
in a diverse group of cancers including: seminomas [11],
pancreatic [12] and gastric [13] adenocarcinomas, squamous cell
carcinomas [14]; and sarcomas [15]. In sarcomas [15] and
pancreatic [12] cancers higher Hiwi mRNA levels were predictive
of worse clinical outcomes. These data lead to an obvious
conundrum: why would a gene that is critical for maintaining
genome integrity during development be highly expressed in
cancer? Since the above studies focused exclusively on Hiwi
expression levels in cancer cells, mechanistic insight into Hiwi’s
role in tumorigenesis remains completely unexamined.
Herein we explore the necessity and sufficiency of Hiwi for
tumorigenesis and maintenance of the tumorigenic phenotype using
mesenchymal stem cellsand sarcomas inboth invitro andtransgenic
models.Surprisinglywefindthat Hiwiisdirectlytumorigenic.Wego
on to show that Hiwi mediated DNA methylation is associated with
tumor suppressor gene silencing, thus potentially accounting for
Hiwi-mediated tumorigenesis. Our data reconcile the conundrum of
how Hiwi may act appropriately to promote genomic integrity
during early development (via transposon silencing) and inappro-
priately in adult tissues with subsequent tumorigenesis.
Results
Hiwi inhibits differentiation and promotes
sarcomagenesis
Following previous PCR-based observations that Hiwi is expressed
in sarcomas [15] and that its expression correlates with prognosis
[15], we examined Hiwi protein levels via immunohistochemistry
(IHC) in a large primary human sarcoma tissue microarray (TMA)
composed of numerous soft-tissue sarcomas (previously described by
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were scored from 0 to 2 blindly by sarcoma pathologists. To examine
the relationship between cellular differentiation and tumor grade, we
focused on a panel of liposarcomas, since we have previously shown
that high grade undifferentiated sarcomas (HGUS), dedifferentiated
liposarcomas, pleomorphic liposarcomas, and well differentiated
lipoarcomas correspond to a gradual adipocytic differentiation
spectrum [23]). We noted that Hiwi levels correlated directly with
grade and indirectly with tumor cellular differentiation. Similar
observations were made for other sarcoma subtypes present on the
TMA as well (e.g., leiomyosarcomas (data not shown)) (Figure 1A).
Overall Hiwi is expressed at significantly higher levels (p,0.005) in
undifferentiated sarcoma subtypes compared with more well-
differentiated subtypes (Figure S1). Both tumor grade and tumor
cellular differentiation have been shown to correlate with clinical
prognosis for sarcomas [24]. These data suggest that Hiwi is
Figure 1. Hiwi inhibits differentiation and promotes sarcomagenesis. (A) Immunohistochemical (IHC) analysis of Hiwi on a human sarcoma
tissue microarray (TMA). Ten cases of each subtype (present in triplicate) were scored from 0 to 2 blindly by sarcoma pathologists. Representative
pictures are shown. (B) Top row: IHC analysis reveals Hiwi-MSC clones (3 and 7) have a distinct clumped morphology and highly express Hiwi. Middle
row: Day 21 in osteogenic media. Calcium matrix formation measured by Alizarin Red S stain is decreased in Hiwi-MSCs, approximately 100% versus
5% of cells staining. Bottom row: Day 21 in adipogenic media. Lipid formation measured by Oil Red O stain is decreased in Hiwi-MSCs, approximately
25% versus 1% of cells staining. Experiments were performed in triplicate and representative pictures are shown. (C) Top row: Xenograft tumors
derived from Hiwi-MSCs. Middle row: H&E analysis reveals tumors from Hiwi-MSCs are undifferentiated sarcomas. Bottom row: By IHC analysis, tumors
from Hiwi-MSCs continue to express Hiwi. All experiments were performed in triplicate. (D) Transgenic mouse model of Hiwi forms sarcomas (left
panel) with both well-differentiated and poorly-differentiated sections (H&E panel) and continues to express Hiwi (right panels).
doi:10.1371/journal.pone.0033711.g001
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and thus by definition designates a poor prognostic outcome [24].
To assess whether Hiwi merely associates with inhibition of
differentiation and tumorigenesis, or whether Hiwi may directly
inhibit differentiation and promote sarcomagenesis, we expressed
Hiwi in sarcoma precursors (i.e., mesenchymal stem cells, MSCs;
Figure 1B; Figure S2 and Supporting Information S1).
Hiwi-expressing MSCs (Hiwi-MSC-3&7) and parental MSCs were
cultured in either adipogenic or osteogenic differentiation medium
[18] and, as per standards of the field, were assayed for phenotypic
maturation with either Alizarin-Red-S for bone/calcium miner-
alization or with Oil-Red-O for fat accumulation. Hiwi-expressing
MSCs (Hiwi-MSC-3&7; columns 2 and 3, Figure 1B) show
impaired differentiation into both osteogenic (second row,
Figure 1B) and adipogenic (third row, Figure 1B) mesenchymal
lineages as compared to parental MSCs (pMSC; column 1,
Figure 1B), which readily accumulate mineralized calcium and
form adipocytic foci. We then inoculated Hiwi-expressing MSCs
(Hiwi-MSC-3&7), parental MSCs and a non-expressing, antibiotic
resistant MSC clone (MSC5; isolated from our initial transduction)
into NOD-SCID-Gamma mice. Tumors formed from Hiwi-MSC
-3&7 inoculations after five weeks. Morphological analysis
(Fabrizio Remotti MD, Department of Pathology, CUMC)
showed that Hiwi- MSC 3&7-derived tumors were high grade
sarcomas. Further IHC analysis also showed that they expressed
Hiwi. In contrast to Hiwi-MSC 3&7, parental MSCs and MSC5
formed small fibrous plaques devoid of tumor cells (Figure 1B,
C; Figure S3 and Supporting Information S1).
We further generated transgenic mice expressing Hiwi under
the control of the early mesodermally restricted Prx1 enhancer
element [21]. 51 Prx1-Hiwi expressing progeny have been
generated to date. Early sarcoma formation was identified in
two (4%) of 51 Prx1-Hiwi mice at 12 weeks, in a known Prx1
distribution, that contain both well-differentiated and high grade
components and express Hiwi (Figure 1D). No other develop-
mental or pathological abnormalities were observed in these Prx-
Hiwi transgenic mice. No sarcoma formation was found in
wildtype, Hiwi-non-expressing littermate control mice. Although
we realize this is a low tumor incidence, it is still significantly
higher than deletion of the retinoblastoma tumor suppressor under
the same promoter [25]; suggesting to us that the low incidence
rate may under-represent Hiwi’s tumorigenic potential in this
model. Additionally, soft-agar oncogene colony formation assays
show that Hiwi is sufficient to transform MSCs (p,0.05) and
further cooperates with Ras (Figure S4 and Supporting
Information S1;p ,0.005). Taken together our data suggest
that Hiwi functions as an oncogene.
Hiwi expression correlates with DNA methylation
Since Hiwi orthologs have been implicated in transposon
silencing via DNA methylation [5,6], we examined both the
expression levels of two common transposons (IAP and Line1) and
alsoglobal DNA-methylationlevelsinHiwi-MSCs (Hiwi-expressing
MSCs, clones 3 and 7).GlobalDNAmethylationwasassessed by an
ELISA-like assay, using an antibody against 5-Methyl Cytosine,
which detects cytosine methylation at both CpG sites and non-CpG
sites. Both IAP and Line1 levels were severely reduced (Figure 2A)
while global DNA methylation was significantly increased (approx-
imately 40%, p,0.05; Figure 2B) in Hiwi-MSCs as compared to
non-Hiwi-expressing MSCs (pMSCs & MSC5); suggesting that
Hiwi expression leads to increase in DNA methylation. We then
checked whether the Hiwi-associated increase in global DNA
methylation is reversible with the DNA-methyltransferase inhibitor,
5-azacytidine (Vidaza). Indeed, 5-azacytidine treatment of Hiwi-
MSCs completely (100%, p,0.05) reverses the increase in global
DNA-methylation associated with Hiwi (Figure 2C) suggesting
that DNMTs may be crucial intermediaries in Hiwi-mediated
methylation. Of note, we did not observe any decrease in global
DNA methylation following treatment of non-Hiwi-expressing
MSCs with 5-azacytidine (data not shown), which may be reflective
of the lower baseline global DNA methylation levels in those cells.
Having established a direct correlation between Hiwi, DNA
methylation, and Hiwi-associated DNA methylation reversibility
via DNA-methyltransferase inhibitors, we examined the levels of
proteins known to modulate DNA methylation: DNA methyl-
transferase 1 (DNMT1), DNA methyltransferase 3 (DNMT3a),
and methyl-binding protein 2 (MBD2). All three were found to
increase in the presence of Hiwi (Figure 2D). Interestingly, we
find no expression changes of DNMT3b in Hiwi-MSCs (data not
shown). Although the exact mechanism of how Hiwi promotes an
upregulation of DNMTs remains unclear, both here and in all
other developmental models where these proteins have been much
more thoroughly explored, the exact mechanism of Piwi is
unknown [1,2,3,4,5,6,7,8,9]. Finally, we show that treatment of
Hiwi-MSCs with 5-azacytidine can reverse Hiwi-mediated
transposon silencing (Figure 2E; Figure S5), restoring IAP and
Line1 transposon expression back to levels comparable with
parental MSCs as the concentration of 5-azacytidine increases. No
such changes in transposons were observed in non-Hiwi expressing
cells, pMSCs and MSC5 (Figure 2E,). Taken together, these data
suggest that Hiwi controls transposon expression directly and is
associated with DNA methylation in Hiwi-transformed MSCs.
Downregulation of Hiwi decreases DNA-methylation and
limits tumorigenic growth
Having shown that Hiwi expression in sarcoma precursors leads
to sarcomagenesis, we queried if Hiwi is necessary for maintenance
of the sarcoma phenotype. We first identified an undifferentiated
sarcoma cell line, MFH (previously characterized by us [17,18],
endogenously expressing Hiwi (Figure S6 and Supporting
Information S1). We then engineered MFH cells to express
doxycycline-inducible Hiwi-short hairpin; (dox-ind-sh-Hiwi MFH;
Figure 3A, top left panel). Both parental MFH cells and sh-
scramble MFH negative control cells continue to express high
levels of Hiwi. In contrast, doxycycline-induced sh-Hiwi MFH
cells have dramatically reduced Hiwi levels (Figure 3A; Clones C
and E were chosen for further analyses). Although MFH cells do
not undergo induced mesenchymal differentiation [17,18], dox-
ind-sh-Hiwi MFH cells are able to undergo mesenchymal
differentiation following doxycycline induction and exposure to
differentiation medium (Figure 3B, osteogenic differentiation is
shown with Alizarin Red S). In contrast, in the absence of
doxycycline (parental MFH cells) rapidly overgrow and die (data
not shown and as previously described [18,26]). Colony formation
is significantly reduced to about 40% of untreated control for dox-
ind-sh-Hiwi MFH clone C and to about 20% of untreated control
for dox-ind-sh-Hiwi MFH clone E (p,0.001 for clone C and
p,0.005 for clone E; Figure 3C). Concurrent with down-
regulation of Hiwi, we observe a significant decrease in global
DNA-methylation (approximately 70%, p,0.05; Figure 3D). In
agreement, 5-azacytidine treatment of sh-Hiwi MFH cells (in the
absence of doxycycline) results in elimination of colony formation
(Figure 3E), similar to that seen in doxycycline-induced sh-Hiwi
MFH (Figure 3D). Colony formation during 5-azacytidine
treatment was reduced to about 25% of untreated control for
sh-Hiwi MFH clone C and to about 50% of untreated control for
sh-Hiwi MFH clone E (combined p,0.01 for both clones). Of
note, we previously published on the general insensitivity of
Hiwi Mediated Tumorigenesis and DNA Methylation
PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e33711Figure 2. Hiwi expression correlates with DNA methylation. (A) IAP and Line1 transposon expression is decreased in Hiwi-MSCs. IAP and Line1
semi-quantitative PCRs were run for 25 cycles. Actin is a loading control. (B) Global DNA methylation is increased in Hiwi-MSCs. Error bars represent
standard error. *=p,0.05 by Student’s T Test (C) Global DNA methylation is decreased to non-detectable levels (ND) after 18 h treatment with 10 uM
5-azacytidine in Hiwi-MSCs. Lower doses of 5-azacytidine (including 1 uM) did not change DNA methylation levels. Error bars represent standard error
*=p,0.05 by Student’s T Test (D) Western blots of indicated proteins reveal increased expression of DNMT1, DNMT3a and MBP2 in Hiwi-MSCs. Actin
is a loading control. (E) Treatment of Hiwi expressing MSCs with 0 uM, 5 uM, 10 uM, or 50 uM 5-azacytidine for 18 h restores IAP and Line1
transposon expression in a dose-dependent manner. IAP and Line1 quantitative RT-PCRs were run and parental MSC of each 5-azacytidine
concentration were used to normalize the rest of the samples at that concentration. Error bars represent standard error. All experiments were
performed in triplicate.
doi:10.1371/journal.pone.0033711.g002
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that Hiwi expressing tumors may be an exception. Taken together
these results indicate that Hiwi is necessary for maintenance of the
tumorigenic phenotype of Hiwi-expressing cells.
Global DNA methylation decrease and growth delay were
common to both Hiwi down-regulation and DNA-methyltrans-
ferase inhibitor treatment, but to address whether the specific
mechanism was the same, we performed a temporal gene
expression profiling (Affymetric U133 Plus 2.0 Arrays) on sh-Hiwi
MFH cells after Hiwi down-regulation (via doxycycline induction)
or 5-azacytidine treatment. Using unsupervised hierarchical
clustering of the whole gene sets of both conditions, we find that
Figure 3. Down-regulation of Hiwi decreases DNA-methylation and limits tumorigenic growth. (A) Verification of inducible sh-Hiwi MFH
clones by immunohistochemistry. sh-Hiwi MFH clones C and E were induced with doxycycline for 3 days before IHC analysis. (B) Day 21 in osteogenic
media. Calcium matrix formation measured by Alizarin Red S stain is restored in sh-Hiwi MFH clones C and E (approximately 50% of cells staining),
induced with doxycycline 7 days before addition of differentiation media and continued in doxycycline-spiked media during differentiation. (C)
Doxycycline-induced sh-Hiwi MFH cells at 4 weeks in colony forming assay show decreased colony formation, as compared to uninduced sh-Hiwi
MFH cells. p,0.001 for clone C and p,0.005 for clone E by Student’s T Test (D) Global DNA methylation is decreased in induced sh-Hiwi MFH cells.
Cells were induced with doxycycline for 3 days before DNA was collected and assayed. Error bars represent standard error. *=p,0.05 by Student’s T
Test (E) Untreated sh-Hiwi MFH cells or treated with 1 uM 5-azacytidine at 4 weeks in colony forming assay. 5-azacytidine treatment decreases colony
formation capacity. Combined p,0.01 by Student’s T Test. All experiments were performed in triplicate. Representative pictures are shown.
doi:10.1371/journal.pone.0033711.g003
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with early time points (24–48 hrs) of 5-azacytidine treatment, and
similarly, longer down-regulation (4–7 d) of Hiwi associates with
longer treatment with 5-azacytidine (Figure 4A). Overlap of
differentially expressed genes in both array sets (Figure S7 and
Supporting Information S1) shows that at early time points,
75% of the genes that are differentially expressed following Hiwi
down-regulation are also differentially expressed during 5-
azacytidine treatment; and over 99% of these overlapping gene
changes trend similarly. At later time points, 50% of the genes that
are differentially expressed following Hiwi down-regulation are
also differentially expressed following 5-azacytidine treatment,
with 93% of these overlapping gene changes trending similarly.
These data suggest that 5-azacytidine treatment of MFH cells
mechanistically mimics Hiwi down-regulation by targeting the
same genes.
We then examined the methylation changes in 27,000 CpG
island covering 14,495 genes that occur during Hiwi down-
regulation in doxycycline-inducible sh-Hiwi MFH cells using
Illumina Meth27 arrays before and after 2, 4 and 7 days of
doxycycline induction. Despite our data showing that global DNA
methylation directly correlates with Hiwi expression (Figures 2
and 3), no overall change in CpG island methylation was
observed following Hiwi down-regulation (Figure 4B). We did
identify 18 CpG islands that decreased by at least 10% (i.e.,
beta.0.1) (Figure S8 and Supporting Information S1;
Table S1) following Hiwi down-regulation after 7 days in both of
our inducible sh-Hiwi MFH clones C & E (no significant changes
in DNA methylation were observed at earlier time points).
However, the 17 genes associated with these 18 CpG islands did
not show a simultaneous increase in gene expression following
Hiwi down-regulation nor did they show a decrease in Hiwi-MSCs
as compared to parental MSCs (Figure S9 and Supporting
Information S1). And finally an equal number of CpG islands
can readily be observed (Figure 4B) that gain CpG methylation
following Hiwi down-regulation. These data suggest that CpG
methylation status of genes (at least the 14,495 on the Illumina
Meth27 array) are not affected; and thus that the overall change in
global DNA methylation observed may be accounted by either
DNA-methylation of repetitive elements (non-gene regions) or
non-CpG gene methylation.
Assessment of Hiwi target genes
To explore further the potential relationship between Hiwi
associated DNA methylation and the resultant effects on genes we
performed global gene expression analysis and subsequently
focused on a group of tumor suppressor genes (TSGs) [27] that
were at least 1.5 fold: (1) down-regulated in Hiwi-MSCs as
compared to parental MSCs; (2) up-regulated in dox-ind-sh-Hiwi
MFH cells following 7 days of doxycyline; and (3) to ensure that
these genes were DNA methylation dependent, further up-
regulated following 5-azacytidine treatment of MFH cells
(Figure 5A). This overlap gave rise to 19 genes (Figure 5B).
Since Rb1 was identified in this set and its methylation has been
thoroughly studied, we further assayed its promoter via bisulfite
sequencing as well as the Line1 regulatory element (Figure S10).
In agreement with our CpG promoter methyl array results, there
are no changes in the methylation status of the Rb1 promoter
CpG sites as Hiwi levels change (Figure S10, top and middle
graphs). Additionally, we find that the Line1 transposon CpG sites
also remain unchanged as Hiwi level change (Figure S10, bottom
graph). These data suggest that because no methylation changes
occur in these methylation-dependent genes, Hiwi-associated
DNA methylation is non-CpG sites methylation. We went on to
further examine the methylation of Line1 and IAP transposon
regions before and after treatment with 5-azacytidine in Hiwi-
MSCs (Figure S11 and Supporting Information S1). The
methylation of these regions remains unchanged during 5-
azacytidine treatment, further suggesting that Hiwi-associated
methylation is non-CpG methylation. In agreement with our
promoter CpG methyl array (Figure 4B), no methylation changes
at any CpG islands (increase or decrease) in these DNA
methylation dependent genes (Figures 2, 3 and 5A) were
observed (Figure S9 and Supporting Information S1).
However, since cell cycle genes were over-represented in the 19
TSGs selected, and upon further examination several additional
cyclin dependent kinase inhibitors (CDKIs) could be identified
immediately below our threshold (data not shown), we further
focused on CDKIs p21, p27 and p15.
We validated the above CDKIs as responsive at the protein level
to Hiwi. CDKIs decrease in Hiwi-MSCs and increase in sh-Hiwi
MFH upon doxycycline induction (Figures 6A, B). We further
performed IHC on the human sarcoma tissue microarray used to
assess Hiwi (Figure 1A); and show that p15, p21, and p27 show a
tight IHC-based inverse correlation to Hiwi levels (Figure 6C).
Ten cases of each subtype (present in triplicate) were scored from 0
to 2 blindly by sarcoma pathologists for each of the indicated
proteins. Average scores are plotted here. Importantly, another
CDKI, p16, which was not identified in our screen, does not show
such a correlation at the IHC level. Previous analyses have only
inversely linked p27 to sarcoma grade [28]. Thus our demonstra-
tion of an inverse relationship to Hiwi for p15, p21 and p27,
combined with our functional data, leads us to conclude that our
observations in model systems apply to human sarcomas. Based on
the latter data, although we cannot absolutely exclude that DNA
methylation is occurring at a non-canonical CpG sites, the lack of
any detectable methylation via sequencing suggests to us that
DNA-methylation is not occurring at the promoters of Hiwi
associated DNA-methylation dependent genes.
Discussion
Using primary mesenchymal stem cells, transgenic mouse
models and human tumor samples we show here that: (1) Hiwi
is directly tumorigenic; (2) Hiwi-expressing tumors may be
addicted to Hiwi expression; (3) Hiwi mediated tumorigenesis is
associated with global DNA-hypermethylation and is reversible
using DNA-methyltransferase inhibitors; (4) Hiwi associated global
DNA-hypermethylation occurs at non-promoter CpG regions; and
(5) Hiwi levels correlate inversely with levels of known tumor
suppressor genes. To the best of our knowledge, this is the first
mechanistic examination of Hiwi functionality in a mammalian
cancer context. Our studies reveal not only a novel oncogenic role
for Hiwi as a driver of tumorigenesis, but also that the use of
epigenetic agents may be clinically beneficial for treatment of
tumors that express Hiwi. Additionally, our data show that Hiwi-
mediated methylation is associated with DNA hyper-methylation
with subsequent genetic and epigenetic changes that favor a
tumorigenic state, reconciling the outstanding conundrum of how
Hiwi may act appropriately to promote genomic integrity during
early development (via transposon silencing) and inappropriately
in adult tissues with subsequent tumorigenesis.
Our data suggest that Hiwi is directly tumorigenic in multiple
assays, although a direct genetic basis for Hiwi up-regulation in
cancer is still lacking. We have assayed for Hiwi chromosomal
amplification using the sarcoma tissue microarray and correlated
Hiwi IHC-based expression to Hiwi chromosomal amplification.
Only one case out of 45 examined carried a true chromosomal
Hiwi Mediated Tumorigenesis and DNA Methylation
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and Supporting Information S1). Hiwi cDNA has been
independently isolated from several human cancers and developing
sperm [11,13] without sequence divergence; thus although we
cannot ruleout a stabilizing mutation, itseemsunlikely. Sincepart of
the tumorigenic process involves a recapitulation of the embryonic
state, similar mechanisms that up-regulate Hiwi during embryolog-
ical development may result in Hiwi’s up-regulation in cancer.
Despite the tight correlations between Hiwi expression, global
DNA methylation, and tumorigenesis provided herein; several
pieces still need to be elucidated. In our models and others [29,30]
Hiwi is predominantly cytoplasmic. Furthermore, the protein-level
up-regulation of DNMT1, DNMT3a and MDB2 (Figure 2D)i s
post-transcriptional (RNA levels do not change in either Hiwi-
MSCs compared to parental cells or in sh-Hiwi MFH before and
after doxycycline induction, data not shown). These data together,
and given previous reports of Hiwi’s interaction with ribosomes
[31] and its cytoplasmic localization, Hiwi-associated DNA-
methylation may involve as yet unidentified control of DNMT
translation. The exact relationship between Hiwi and its
mechanistic epigenetic control is an ongoing endeavor both in
our laboratory within a cancer context and in the laboratories of
many others interested in the role of Piwi proteins in development
[1,2,3,4,5,6,7,8,9].
Even in mice where Piwi orthologs have been more extensively
studied in terms of DNA methylation [7,8] the exact mechanism by
which Piwi family members mediate DNA methylation during
normal embryological development is still unclear. Our data that (1)
Hiwi translationally up-regulates DNMTs, (2) global DNA
methylation (at CpG and non-CpG sites) correlate directly with
Hiwi levels, (3) promoter CpG methylation does not change during
Hiwi down-regulation and (4) Hiwi down-regulation and 5-
azacytidinetreatmentaremechanistically similar,takenalltogether,
suggest that Hiwi-associated DNA-methylation is occurring globally
at non-CpG promoter areas and/or at repetitive element regions.
Our inability to detect any DNA promoter methylation via
sequencing at either the Line1 element or at the Rb promoter
(two transcripts heavily regulated by Hiwi) leads us to suggest that
promoters are not methylated. DNA methylation at repetitive
element regions has been previously reported to result in long
distance gene silencing via chromatin remodeling [32,33] and given
previous reports that Piwi proteins associate with small RNAs
(piRNAs) with homology to repetitive elements [10,34] may explain
the lack of gene promoter methylation observed in our systems. On
this note a recent report by Sugimoto et al [35] found that another
Hiwi family member, Hiwi2, induces p16 silencing via histone 3
lysine 9 methylation, but not, however, gene promoter DNA
methylation. To examine the possibility of Hiwi-mediated histone
methylation changes, we performed immunofluorescence staining
for varioushistone marks (FigureS13A–F) on our dox-ind-sh-Hiwi
MFH cells. However, we were not able to discern any alterations in
any histone marks examined during Hiwi down-regulation,
although we do not doubt that just as reported by Sugimoto et al,
promoters of silenced genes will be associated with silencing
chromatin marks. Regardless, we believe that stringent statistical
cut-offs and the overlapping of gene lists from several independent
analyses, clones, and model organisms, resulted in a gene list that
likely belies the true extent of gene silencing found in Hiwi
expressing cancers. The identified genes are likely to be extremely
specific and serve as the basis for further studies of Hiwi mediated
gene regulation, tumorigenesis and DNA methylation.
Our observation that Hiwi-mediated tumorigenesis is associated
with increased global DNA methylation is somewhat discordant
from the more widely accepted notion that global methylation levels
are decreased in a variety of human cancers despite specific increase
in both promoter and non-promoter CpG island methylation. Thus
the global hypomethylation observed in cancer is believed to
predominantlyoccurviarepetitiveelementhypomethylation (which
accounts for a significant portion of the human genome; reviewed
extensively in [36,37]). As a result of its inherent developmental
preference for repetitive element silencing via DNA methylation,
Hiwi maypreferentiallytarget repetitiveelementsformethylationin
cancer cells thus mechanistically accounting for an exception to the
commonly observed global hypomethylation of cancer.
In conclusion, numerous recent reports of high levels of Hiwi in
all cancers examined have raised important questions about the role
of Hiwi in adult neoplastic tissues and seem to contradict its known
roles in maintaining genome integrity in both germline and somatic
stem cells. The data presented here are, to our knowledge, the first
to define a causative oncogenic role for Hiwi in human cancer and
to elucidate that DNA methylation dependent silencing of tumor
suppressor genes accounts for the tumorigenesis. In doing so, we not
only reconcile Hiwi’s genomic protective and tumorigenic proper-
tiesbutalsoprovide a therapeuticrationalefortreating patientswith
Hiwi-expressing tumors epigenetically by means of DNA-methyl-
transferase inhibitors.
Methods
Colony formation assays
Cellsweresuspendedin0.3%agar(Sigma)inculturemediumand
plated into 6 well plates, with a base layer of 0.6% agar in culture
medium. For doxycyline and 5-azacytidine treatments, cells were
pre-treated for 7 days in culture before beginning colony formation
assay. Cells were kept in drug-spiked media during the assay and
monitored for colony formation. Pictures were taken after 4 weeks.
Experiments were performed 2 times, each time in duplicate.
Quantitative and semi-quantitative RT PCR
Total RNA was extracted from the indicated cell lines using
RNeasy RNA extraction kit (Qiagen) according to the manufac-
turer’s protocol. 1 mg of RNA was transcribed into cDNA using
Super-Script III First Strand Synthesis System for RT-PCR
(Invitrogen). To assess the expression levels of IAP, Line1, and b-
actin control semi-quantitative RT-PCR reactions containing
Platinum Blue PCR mix (Invitrogen), 1 ul cDNA and correspond-
ing primers were run at the following PCR program: 95uC62 min;
95uC630 s, 55uC630 s, 68uC645 s for 28 cycles; 6865 min.
Quantitative RT-PCRs were performed by the Taub Core Facility
(CUMC). Sequences for IAP and Line1 primers for both semi-
quantitative and quantitative RT-PCRs, from Aravin et al [16],
were as follows: Line1 forward: 59 GAGAACATCGGCACAA-
CAATC; Line1 reverse: 59 TTTATTGGCGAGTTGAGACCA;
IAP forward: 59 CAGACTGGGAGGAAGAAGCA; IAP reverse:
59 ATTGTTCCCTCACTGGCAAA. Experiments were per-
formed in triplicate.
Figure 4. Hiwi down-regulation and 5-azacytidine treatment are mechanistically similar. (A) Gene expression profiles of sh-Hiwi MFH cells
treated with 1 uM or 5 uM 5-azacytidine cluster with gene expression profiles of doxycycline-induced sh-Hiwi MFH cells, using the whole gene set
from both treatments. (B) Meth27 Illumina array of methylation of 27000 CpG site changes in sh-Hiwi MFH cells uninduced (x-axis) or induced with
doxycycline for 7 days (y-axis). Graph shows all CpG islands and reveals no global shift in CpG methylation.
doi:10.1371/journal.pone.0033711.g004
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PLoS ONE | www.plosone.org 9 March 2012 | Volume 7 | Issue 3 | e33711Assessment of DNA methylation levels
Genomic DNA was isolated by DNeasy Blood and Tissue Kit
(Qiagen). Global DNA methylation levels were assessed by
Methylflash Methylated DNA Quantification Kit (Epigentek)
and read on a plate reader at 490 nm, according to manufactur-
er’s protocol. Experiments were performed in triplicate.
Immunohistochemistry (IHC)
IHC was performed as previously described by us [17]. Briefly,
formalin-fixed, paraffin-embedded (FFPE) tissues were rehydrated
and treated with citric buffer for antigen retrieval. Slides were
blocked with 10% horse of goat serum in 2% BSA-PBS and then
incubated in primary antibody (diluted in 2% BSA-PBS) overnight
Figure 6. CDKIs are decreased in Hiwi–MSCs. (A) Western blot of indicated proteins reveals that p21 and p27 are decreased in Hiwi-MSCs. (B)
Western blot of indicated proteins reveals that p21, p27 and p15 are increased in sh-Hiwi MFH cells that have been induced with doxycycline for 4 or
7 days. (C) IHC analysis of a human sarcoma TMA reveals a tight inverse correlation of p21, p27 and p15 expression (x-axes) to Hiwi expression (y-axis)
(R
2=0.764; R
2=0.8679; R
2=0.7539, respectively) but no such correlation for p16 expression (x-axis) to Hiwi expression (y-axis) (R
2=0.5418). Ten cases
of each subtype (present in triplicate) were scored from 0 to 2 blindly by sarcoma pathologists. Average scores for each case are plotted here.
doi:10.1371/journal.pone.0033711.g006
Figure 5. Assessment of Hiwi target genes. (A) Top panel: Affymetrix 430 2.0 array of gene expression changes in parental MSCs (x-axis) or Hiwi-
MSCs (y-axis). Affymetrix U433 array of gene expression changes in sh-Hiwi MFH cells uninduced (x-axis) or induced for 7 days with doxycycline (y-
axis) (middle panel) or untreated (x-axis) and after 7 days of 1 uM 5-azacytidine (y-axis) (bottom panel). Arrow indicates genes used in overlap
analysis. (B) Overlap of Tumor Suppressor Genes (TSG) as described. All 19 overlapping TSGs are listed here.
doi:10.1371/journal.pone.0033711.g005
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antibody (Vector Labs) incubation, slides were developed with 3,3-
Diaminobenzidine (DAB) and counterstained with Hematoxyalin.
For cells, fixation was performed with 50% Methanol/Acetone for
10 minutes, then blocking, primary antibody incubation, and
detection was performed as for FFPE IHC. Primary antibodies
used in these studies: Hiwi (Abcam, 12337); p15 INK4b (Novus
Biologicals, NB100-91906); p16 (BD Pharmingen, G175-405); p21
(Santa Cruz, sc-6246); p27 (Santa Cruz, sc-528).
Sarcoma tissue microarray (TMA)
The TMA contained 10 cases of each sarcoma subtype in
triplicate. For TMA analysis, IHC staining was scored on a scale of
0 to 2 by multiple pathologists. The average score for each sarcoma
subtype was calculated and representative pictures are shown.
Western blotting
Standard western blotting technique was used. Briefly, protein
lysate was collected from cells with RIPA buffer (Boston
BioProducts) and 50 ug were run on a 4–20% Tris-glycine gradient
gel (Invitrogen). Nitrocellulose membranes were incubated over-
night at 4uC in primary antibody: DNMT1 (1:500, abcam 92453);
DNMT3a(1:500, abgent AP1034a); MDB2 (1:1000,abcam38646);
Hiwi (1:500 ProSci 45-735P).
Bone and fat differentiation
Bone or fat differentiation was assessed in MSCs after 21 days in
bone or fat differentiation media, as previously published [18].
Approximate percentage of differentiated cells was calculated based
on the average alizarin red s or oilred o stainingover 3 independent
experiments.
Ethics statement
All mouse experiments for this specific study were approved by the
Columbia IRB as described under protocol AAAA9669 and in
accordance with Columbia University Animal Welfare and IUCAC
policy.
Xenograft generation
NOD-SCID mice were subcutaneously injected, in triplicate,
with 1 million cells of each indicated cell type, as described
previously [1]. Tumor formation was monitored for 5 weeks and
mice were sacrificed when tumor size reached 1 cm, in accordance
with Columbia University Animal Welfare and IUCAC policy
under IRB protocol AAAA9669.
Generation of Hiwi expressing mesenchymal stem cells
(Hiwi-MSCs) and inducible Hiwi knock down MFH cells
Details on cell lines, growth conditions, differentiation induction
and assessment have been previously described by us [17,19].
Hiwi-MSCs were generated by cloning Hiwi cDNA (gift of Dr. G.
Hannon) into the pLENTI vector (Invitrogen). Transfection into
293FT cells/infection into MSCs was performed with the
ViraPower system (Invitrogen). Doxycycline-inducible short hair-
pin Hiwi-MFH cells were generated by transfection of lentiviral
pTRIPZ Hiwi short hairpin vector (OpenBiosystems) into 293FT
cells and then infection into MFH cells. 0.5 ug/ml doxycycline in
growth media was used to induce sh-Hiwi expression. sh-Hiwi
constructs are 3 separate shRNA plasmids against Hiwi, pooled
and co-transfected into MFH cells.
Generation of Prx1-Hiwi transgenic mice
The human Hiwi gene was subcloned under the control of the
Prx1 promoter [20,21] (gift of Dr. C. Tabin). Founders with
highest transgene expression were chosen for further analysis.
Gene expression profiling
RNA from the indicated cell lines were hybridized to Affymetrix
HG U133 (human) or Affymetrix 430 2.0 (mouse) oligonucleotide
arrays per standard protocols of the Columbia Genomics Core
Facility. Class-comparison analysis using two-sided Student t-tests
identified mRNAs that were differentially expressed between
indicated samples (p,0.05). Raw data will be deposited in the
public repository.
Promoter methylation profiling
Promoter methylation profiling was done using Illumina
Meth27 promoter arrays. Samples were run at Roswell Park
Cancer Institute Genomics Facility. Average beta values, corre-
sponding to amount of methylation, were then analyzed using
Genespring software.
For additional information please see Supplementary Methods
in Supporting Information S1.
Bisulfite quantitative PCR
Bisulfite quantitative PCRs for Line1 and IAP on Hiwi-MSCs
wereperformedatthe TaubInstituteCoreFacility(CUMC).Briefly,
Hiwi-MSCs were treated for 18 h with the indicated concentration
of 5-azacytidine and then DNA was collected. After quantitative
PCR for either Line1 or IAP, the resulting PCR amplicon was
bisulfite converted to assess methylation in that region. Primers for
IAP and Line1 from Lane et al [22], were as follows: Line1 forward:
59 GTTAGAGAATTTGATAGTTTTTGGAATAGG; Line1 re-
verse: 59CCAAAACAAAACCTTTCTCAAACACTATAT; IAP
forward: 59TTGATAGTTGTGTTTTAAGTGGTAAATAAA;
IAP reverse: 59AAAACACCACAAACCAAAATCTTCTAC.
Supporting Information
Supporting Information S1 Supporting Information includes
supporting text further explaining data in supporting figures,
supporting methods used in this study, and supporting references.
(DOC)
Figure S1 Hiwi is highly expressed in human undiffer-
entiated sarcoma samples. Immunohistochemical (IHC)
analysis of Hiwi on a human sarcoma tissue microarray (TMA).
Ten cases of each subtype (present in triplicate) were scored from 0
to 2 blindly by sarcoma pathologists. HGUS= high grade
undifferentiated sarcoma. Average scores are plotted here for
each subtype. Error bars represent standard error **=p,0.005 by
Student’s T-Test
(TIF)
Figure S2 Validation of Hiwi-MSCs. (A) Parental MSCs,
MSC5 (a clone which is selection-marker resistant but doesn’t
express Hiwi), and Hiwi–expressing clones 3 and 7 were analyzed
by quantitative RT-PCR for Hiwi expression. MSC-Hiwi 7 was
arbitrarily set at 1. (B) MSC clones were analyzed by Western Blot
for Hiwi expression levels. MSC-Hiwi 3 and 7 were positive clones,
whereasMSC2,5,and6gainedselectionmarkerresistancewithout
expressing Hiwi. MSC5 was chosen for further experiments. AGS
and N87 gastric cancer cell lines have been previously reported as
positive controls for Hiwi expression. See Supporting Information
S1 for further explanation of non-specific bands.
(TIF)
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a xenograft model. Quantification of average xenograft size in
grams, after 5 weeks of monitoring. Xenografts were diagnosed
histo-pathologically to be high grade undifferentiated sarcomas.
Error bars represent standard error and xenografts were
performed in triplicate. *=p,0.05 by Student’s T-Test
(TIF)
Figure S4 Hiwi and Ras cooperate to become highly
oncogenic in MSCs. MEFs (left column) or MSCs (right column)
were transfected with either Hiwi alone, Ras alone or with both Hiwi
and Ras and then put into colony formation assays. At 4 weeks in
colony formation assay, both Hiwi alone and Ras alone formed
colonies in MSCs (p,0.05 compared to untransfected control) and
together they formed significantly more colonies (p,0.005 compared
to untransfected control). No significant changes in colony formation
were observed in the transfected MEFs (p.0.5 for all transfections
compared to untransfected control). All experiments were performed
in triplicate. Representative pictures are shown here.
(TIF)
Figure S5 Treatment of Hiwi-MSCs with 5-azacytidine
can reverse Hiwi-mediated transposon silencing. (A)
Semi-quantitative RT-PCR for Line1 and IAP transposon
expression on Hiwi-MSCs treated 18 h with the indicated
concentration of 5-azacytidine. Actin is a loading control.
Experiments were performed in triplicate. (B) Semi-quantitative
RT-PCR for Line1 and IAP transposon expression on Hiwi-MSCs
treated 18 h with 50 uM of 5-azacytidine or 5-aza-2-deoxycytidine.
Actin isa loadingcontrol.Experimentswereperformedintriplicate.
(TIF)
Figure S6 Expression of Hiwi in sarcoma cell lines. (A)
Quantitative RT-PCR of Hiwi in a panel of human sarcoma cell
lines reveals that MFH has high Hiwi RNA levels. (B) Immuno-
histochemical analysis of Hiwi in a panel of human sarcoma cell
lines reveals that MFH has high Hiwi protein levels.
(TIF)
Figure S7 Hiwi down-regulation and 5-azacytidine
treatment are mechanistically similar. (A) Venn diagram
of overlapping differentially expressed genes in both sh-Hiwi MFH
cells and in 5-azacytidine-treated MFH cells. At early time points,
over 75% of differentially expressed genes following Hiwi down-
regulation are also differentially-expressed during 5-azacytidine
treatment.99%oftheoverlappinggenesmoveinthe same direction
in both conditions. (B) At late time points, over 50% of differentially
expressed genes following Hiwi down-regulation are also differen-
tially-expressed during 5-azacytidine treatment. 93% of the
overlapping genes move in the same direction in both conditions
(TIF)
Figure S8 Genes with CpG site promoter hypo-methya-
tion in sh-Hiwi MFH cells. Analysis of Illumina Meth27
promoter methylation arrays reveals only 18 CpG sites that show
at least a 10% decrease in methylation after 7 days of doxycycline
treatment of sh-Hiwi MFH cells. Genes to which the CpG sites
belong are identified here.
(TIF)
Figure S9 CpG methylated genes do not correlate to
genes expression changes in sh-Hiwi MFH cells and
Hiwi MSCs. (A) Gene expression profiles of the 17 identified
genes with CpG site hypo-methylation, after 0, 2, 4 or 7 days of
doxycycline induction of sh-Hiwi MFH cells. While corresponding
CpG sites are hypo-methylated, there is no corresponding increase
in gene expression. (B) Gene expression profiles of the 17 identified
genes with CpG site hypo-methylation in Hiwi-MSCs. Conversely,
thereis nodecreaseinexpression ofthesegenes.Because eachofthe
17 identified genes contains multiple spots on the array,
corresponding to multiple Gene IDs, multiple rows for each gene
are shown in both (A) and (B).
(TIF)
Figure S10 Methylation of Rb1 and Line1 promoter
CpG islands do not change as Hiwi levels change. Bisulfite
sequencing of Rb1 promoter CpGs in Hiwi-MSCs (top graph) and
in sh-Hiwi MFH cells (middle graph) reveal no methylation
changes as Hiwi levels change. Similarly, bisulfite sequencing of
Line1 CpGs in Hiwi-MSCs (bottom graph) reveal no methylation
changes as Hiwi levels change.
(TIF)
Figure S11 IAP and Line1 transposon methylation is
unchanged in Hiwi-MSCs. Quantitative PCR of IAP or Line1
transposon expression, followed by bisulfite conversion, on parental
MSCs, MSC5, Hiwi-MSC3 and Hiwi-MSC7 treated with the
indicated concentration of 5-azacytidine for 18 h. Experiments were
performed in triplicate. Error bars represent standard error.
(TIF)
Figure S12 Hiwi is not chromosomally amplified in
Hiwi-expressing sarcomas. DNA FISH was performed on
the human sarcoma tissue microarray, using a probe against the
Hiwi locus on chromosome 12. (i) Analysis of the sarcomas reveals
only 1 out of 45 cases that has a true amplification of Hiwi, a
dedifferentiated liposarcoma. (ii) A few cases (5 out of 45) have a
copy number increase of Hiwi. (iii) However, the majority of cases
(39 out of 45), including all HGUS Hiwi-expressing cases, have no
chromosomal amplification of Hiwi.
(TIF)
Figure S13 Epigenetic histone marks are unchanged in
doxycycline-induced sh-Hiwi MFH cells. Immunofluores-
cence on sh-Hiwi MFH cells, either uninduced or induced for 7days
with doxycycline to knock down Hiwi levels, for the following
histone 3 lysine or arginine marks (A) H3K4me; (B) H3K4me; (C)
H3K27me; (D) panH3Rme2; (E) H3R2me; (F)H3R17me.
(TIF)
Table S1 Promoter methylation in dox-ind-sh-Hiwi MFH cells
does not change compared to uninduced control MFH cells. Raw
beta values from the Illumina promoter meth27 arrays are shown
here. Beta values are between 0 and 1, corresponding to
unmethylated and completely methylated, respectively.
(XLS)
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